HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dan Li Selected Research

BRL 44408

10/2020α2A -AR antagonism by BRL-44408 maleate attenuates acute lung injury in rats with downregulation of ERK1/2, p38MAPK, and p65 pathway.
2/2018[BRL-44408 maleate, the antagonist of α2A-adrenoceptor, attenuates endogenous lipopolysacchride-induced acute lung injury through inhibiting the mitogen-activated protein kinase kinase/extracellular regulated protein kinases signaling pathway in mice].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dan Li Research Topics

Disease

548Neoplasms (Cancer)
12/2022 - 04/2002
108Inflammation (Inflammations)
12/2022 - 11/2006
107Infections
07/2022 - 01/2003
83Neoplasm Metastasis (Metastasis)
11/2022 - 05/2009
59Carcinogenesis
11/2022 - 01/2008
49Hepatocellular Carcinoma (Hepatoma)
01/2022 - 01/2003
45Breast Neoplasms (Breast Cancer)
10/2022 - 03/2009
39Lung Neoplasms (Lung Cancer)
08/2022 - 06/2010
39Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2022 - 07/2009
38Stomach Neoplasms (Stomach Cancer)
11/2022 - 01/2008
33Fibrosis (Cirrhosis)
08/2022 - 03/2003
27Cardiovascular Diseases (Cardiovascular Disease)
08/2022 - 12/2009
27Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 04/2005
26Atherosclerosis
02/2022 - 11/2008
25Hypertension (High Blood Pressure)
05/2022 - 09/2006
24COVID-19
07/2022 - 01/2020
24Cataract (Cataracts)
01/2022 - 01/2015
23Adenocarcinoma
01/2022 - 01/2007
22Prostatic Neoplasms (Prostate Cancer)
10/2022 - 10/2005
21Parkinson Disease (Parkinson's Disease)
06/2022 - 05/2010
21Leukemia
04/2022 - 04/2006
21Pancreatic Neoplasms (Pancreatic Cancer)
02/2022 - 01/2012
18Neurodegenerative Diseases (Neurodegenerative Disease)
09/2022 - 10/2012
18Insulin Resistance
07/2022 - 01/2012
18Glioma (Gliomas)
02/2022 - 08/2006
18Carcinoma (Carcinomatosis)
04/2021 - 12/2003
17Sepsis (Septicemia)
07/2022 - 05/2010
17Uterine Cervical Neoplasms (Cancer of the Cervix)
04/2022 - 01/2007
17Hypoxia (Hypoxemia)
03/2022 - 08/2007
17Neuroblastoma
01/2022 - 08/2007
16Reperfusion Injury
12/2022 - 01/2009
16Wounds and Injuries (Trauma)
11/2022 - 01/2008
16Liver Neoplasms (Liver Cancer)
03/2022 - 01/2003
15Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 04/2002
15Body Weight (Weight, Body)
01/2022 - 02/2008
14Pain (Aches)
06/2022 - 06/2009
14Hemorrhage
02/2022 - 09/2011
14Ischemia
01/2022 - 01/2006
14Heart Failure
12/2021 - 09/2012
13Melanoma (Melanoma, Malignant)
01/2022 - 01/2007
13Asthma (Bronchial Asthma)
01/2022 - 11/2006
13Coronary Artery Disease (Coronary Atherosclerosis)
07/2021 - 08/2011
13Mitochondrial Diseases (Mitochondrial Disease)
01/2021 - 02/2010
12Hematologic Neoplasms (Hematological Malignancy)
12/2022 - 02/2003
12Disease Progression
08/2022 - 01/2003
12Urinary Bladder Neoplasms (Bladder Cancer)
03/2022 - 09/2013
12Myocardial Infarction
01/2022 - 01/2013

Drug/Important Bio-Agent (IBA)

185Proteins (Proteins, Gene)FDA Link
11/2022 - 01/2003
80Biomarkers (Surrogate Marker)IBA
12/2022 - 09/2008
80Pharmaceutical PreparationsIBA
06/2022 - 06/2009
58Biological ProductsIBA
07/2022 - 05/2009
55MicroRNAs (MicroRNA)IBA
06/2022 - 03/2009
52Messenger RNA (mRNA)IBA
01/2022 - 09/2006
45CytokinesIBA
09/2022 - 01/2003
44EnzymesIBA
10/2022 - 01/2003
37DNA (Deoxyribonucleic Acid)IBA
05/2022 - 04/2002
36Glucose (Dextrose)FDA LinkGeneric
07/2022 - 04/2005
36Long Noncoding RNAIBA
02/2022 - 01/2014
35Peptides (Polypeptides)IBA
01/2022 - 11/2007
33Small Interfering RNA (siRNA)IBA
01/2022 - 06/2010
32Therapeutic UsesIBA
12/2022 - 02/2008
24VaccinesIBA
12/2022 - 11/2007
24LigandsIBA
01/2022 - 06/2012
23Anti-Bacterial Agents (Antibiotics)IBA
07/2022 - 08/2007
23RNA (Ribonucleic Acid)IBA
01/2022 - 08/2014
23Transcription Factors (Transcription Factor)IBA
01/2022 - 10/2005
22AntigensIBA
03/2022 - 11/2009
22LipidsIBA
01/2022 - 03/2010
21LipopolysaccharidesIBA
12/2022 - 12/2014
21Reactive Oxygen Species (Oxygen Radicals)IBA
04/2022 - 02/2010
21AntioxidantsIBA
01/2022 - 11/2008
20Interleukin-6 (Interleukin 6)IBA
07/2022 - 01/2007
19Doxorubicin (Adriamycin)FDA LinkGeneric
10/2021 - 06/2012
17CholesterolIBA
10/2022 - 11/2008
17Amyloid (Amyloid Fibrils)IBA
06/2022 - 01/2015
17Matrix Metalloproteinases (MMPs)IBA
05/2022 - 05/2009
17Paclitaxel (Taxol)FDA LinkGeneric
05/2022 - 06/2009
17AntibodiesIBA
01/2022 - 07/2013
17Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 04/2002
17Monoclonal AntibodiesIBA
01/2022 - 06/2007
16Phosphotransferases (Kinase)IBA
11/2022 - 06/2009
16GoldIBA
06/2022 - 03/2011
16Cisplatin (Platino)FDA LinkGeneric
05/2022 - 04/2002
16Indicators and Reagents (Reagents)IBA
03/2022 - 03/2013
16ProdrugsIBA
01/2022 - 01/2012
15Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 11/2007
14Antiviral Agents (Antivirals)IBA
01/2022 - 06/2009
13CalciumIBA
10/2022 - 09/2006
13AcidsIBA
07/2022 - 10/2011
13PolymersIBA
07/2022 - 01/2014
12Chimeric Antigen ReceptorsIBA
05/2022 - 01/2016
12Neuroprotective AgentsIBA
05/2022 - 10/2012
12Caspase 3 (Caspase-3)IBA
03/2022 - 01/2012
12Circular RNAIBA
02/2022 - 01/2019

Therapy/Procedure

237Therapeutics
10/2022 - 01/2003
63Drug Therapy (Chemotherapy)
05/2022 - 04/2002
41Immunotherapy
07/2022 - 11/2007
20Radiotherapy
01/2022 - 01/2012
15Precision Medicine
05/2022 - 01/2014
14Lasers (Laser)
05/2022 - 01/2008